To Congress, From Pharma: Love, Hate And Fresh Ideas For 21^st Century Cures

Industry and key stakeholders weigh in on House Commerce Committee’s first take at biomedical reform; brand companies offer lots of positive feedback but want many modifications; generic companies criticize multitude of new exclusivity provisions for brands.